v" The authors have reported on 108 patients with pituitary macroadenomas (measuring 2 cm in at least one diameter) who underwent 117 transsphenoidal operations and five craniotomies, and were followed for periods ranging from 6 months to 14 years. Vision improved in 90% of the patients. Gross total tumor removal with no evidence of residual tumor tissue demonstrable on the postoperative computerized tomography scan was accomplished in 41% of cases. However, gross total tumor removal is not synonymous with complete tumor removal. Endocrine cure was possible in 25% of prolactin-secreting and 20% of growth hormone-secreting adenomas. The incidence of recurrence was 12%, with the majority occurring from 4 to 8 years postoperatively. Both the tumors with suprasellar extension of more than 2 cm and the hard fibrotic tumors had a higher recurrence rate. Postoperative administration of radiation therapy has been associated with a significantly lower recurrence rate than when this therapy was withheld. Transsphenoidal surgery of pituitary macroadenomas confined to the extra-arachnoid space is associated with a relatively small number of complications. The operative technique used in this series is described.
O
VER the past 15 years, considerable advances have been made in the surgical treatment of pituitary microadenomas, with a high incidence of complete tumor removal reported. 11 '16'17'2~ In contrast, total removal of a pituitary macroadenoma is rare, if at all possible to accomplish, regardless of the technique utilized. In the present study, an attempt has been made to correlate a number of pituitary tumor characteristics with 1) postoperative improvement in visual acuity; 2) the surgeon's ability to carry out a gross total tumor removal; and 3) the rate of recurrences. The operative procedure is described and the long-term follow-up results presented, with special emphasis on the role of postoperative radiation therapy in the prevention of recurrences. A brief review of the pertinent literature and of our own experience with the use of bromocriptine in the treatment of pituitary macroadenomas is also given.
Summary of Cases
A pituitary tumor was classified as a macroadenoma when it measured 2 cm or more in at least one diameter.
This series includes 108 patients with such tumors who were operated on a total of 122 times between December, 1968, and April, 1982 . A transsphenoidal technique was used in all but five operations. Two craniotomies were carried out as part of a combined approach to asymmetrically growing tumors. In three patients, the craniotomy was performed for a recurrence. Our youngest patient was 19 years old and the oldest 73 years of age. There were 62 males and 46 females.
Tumor Classification
Eighty tumors in this series (77%) had a suprasellar extension. Tumor dimensions were obtained from either pneumoencephalotomography or computerized tomography (CT) scanning. The vertical diameter of the suprasellar tumor extension ranged between 5 and 40 mm, with an average of 17 mm. The average sagittal and frontal diameters of the suprasellar tumor extension was 24.5 and 25 mm, respectively. There were 75 tumors growing straight, and nine with an asymmetrical suprasellar growth. Twenty patients had cystic hemorrhagic tumors (18.5%): 65 (60%) of the lesions were soft and 21 (19.5%) were described as hard with numerous fibrous septa. Calcifications and sarcoid nodules were found in one case each.
A pituitary tumor was classified as invasive when the polytomogram or CT scan showed destruction of the sella floor and of the surrounding skull base, or when there was evidence on the CT scan of tumor invasion into the cavernous sinuses, petroclinoid ligaments, or cerebral parenchyma. There were 27 invasive tumors in this series (25%). A pituitary tumor associated with an absent sella floor but which was still contained within the dura mater at the time of surgery was classified as enclosed or noninvasive.
Neuroradiology
All patients in this series were studied with hypocycloidal polytomography. Until the introduction of highresolution CT scanning in the diagnosis of pituitary tumors 9 all patients were also studied with cerebral angiography. Preoperatively, 50 patients in this series underwent pneumoencephalotomography and 81 patients had CT scanning. Over the past 18 months, highresolution CT scans, capable of demonstrating the position and configuration of intracranial carotid arteries and their branches and of providing accurate measurements of the tumor size, have largely obviated the need for cerebral angiography and pneumoencephalotomography. In each case, magnification coronal views and, more recently, sagittal reconstruction views were obtained and were found helpful in surgical strategy.
Surgical Technique
The transsphenoidal approach has been the preferred surgical technique in this series. Because pituitary tumors are extra-arachnoid lesions that displace rather than penetrate the arachnoid membrane, 5 important intra-arachnoid neurovascular structures are not disturbed during a transsphenoidal operation (Fig. 1) . In a procedure to reach a suprasellar tumor extension, the patient's head was extended somewhat more than when attacking a microadenoma. When an invasive tumor was suspected, the operating microscope was placed in position prior to opening the anterior wall of the sphenoid sinus. Wide exposure of the sphenoid sinus and anterior wall of the sella was carried out.
After the tumor was exposed by opening the dura mater, its intrasellar portion was first gutted with pituitary dissectors, loop and ring curettes, or microscissors when tough fibrous septa were present. As the tumor interior was removed, the tumor surface would become slack enough to permit its separation from either the residual normal anterior pituitary or the surrounding dural structures. In patients with no discernible normal anterior pituitary tissue remaining, mobilization of the tumor surface proceeded along the plane between the severely distended and thinned out original pituitary gland capsule which surrounds the tumor parenchyma 5 I. Ciric, et aL and the dura of the sella walls. Gutting of the tumor parenchyma and mobilization of the tumor surface were repeated in an alternating fashion until the reflection of the arachnoid membrane at the level of the diaphragma sellae came into view. With the intrasellar portion of the tumor freed from the surrounding structures and removed, additional gutting of the directly visible suprasellar tumor was then carried out with loop curettes of different sizes (2, 3, 4, or 5 mm), chosen according to the preoperative measurements of the suprasellar tumor extension. A Valsalva maneuver initiated by the anesthesiologist was found helpful at this point in dislodging the arachnoid membrane along with the residual tumor tissue, from the suprasellar space toward the diaphragma sellae and into surgeon's view. The final removal of the tumor dome was accomplished by exerting a gentle pull on the tumor margin while simultaneously dissecting it free from the protruding and by now redundant arachnoid membrane with the use of either a small-diameter suction tip, loop curettes, or microforceps.
At the completion of the procedure, a thin layer of compressed normal anterior pituitary tissue was frequently found adherent to the undersurface of the arachnoid membrane. In cases where the arachnoid membrane was penetrated and a cerebrospinal fluid (CSF) fistula created, the opening was sealed immediately with a graft of fat, fascia, and muscle. Whenever possible, the anterior sella wall was reconstructed with a graft of a piece of nasal cartilage or rib cartilage. The cartilage graft was fitted between the dura and the sella opening. 
Operative Results
Morbidity and Mortality. There was no mortality following 117 transsphenoidal operations for a pituitary macroadenoma. One patient who underwent craniotomy for a recurrent pituitary tumor died from a postoperative intracerebral hemorrhage. Four patients (3.5%) had postoperative CSF rhinorrhea requiring surgical repair of the fistula. In two of these patients the rhinorrhea occurred 6 weeks and 18 months following surgery, respectively. One patient had a ventriculoperitoneal (VP) shunt placed elsewhere for hydrocephalus. In this patient, the onset of rhinorrhea was associated with spontaneous pneumocephalus. Ligation of the VP shunt was necessary to relieve this complication. The second patient with delayed rhinorrhea had been receiving bromocriptine for about 12 months when the fistula formed. In all four patients, the fistula was repaired using the transsphenoidal approach.
There was only one case of meningitis (0.8%) which occurred 18 months postoperatively in the patient with the delayed CSF fistula. Two patients had postoperative ophthalmoplegia: in one it was due to a temporary sixth nerve paresis following a transsphenoidal operation, and in the other to a permanent third nerve paresis following craniotomy for a large and asymmetrically growing pituitary adenoma. Diabetes insipidus lasting longer than 3 months has not been observed in this series.
Visual Symptoms. A preoperative visual deficit was present in 59 patients (Table l) . The most common visual field defect was an incomplete bitemporal hemianopsia. Unilateral blindness with a contralateral field defect, a nasal field defect, a central scotoma, and other field defects were represented as well. There were four cases of pituitary apoplexy (2.7%). One patient with a prolactin-secreting pituitary tumor developed sudden blindness in both eyes after having severe headaches for approximately 24 hours. The hematoma and the residual tumor were removed in an emergency operation using the transsphenoidal technique, resulting in complete restoration of vision in one eye and a residual partial upper quadrant defect in the other. The preoperative and postoperative prolactin levels in this patient were 1630 and 3.5 ng/ml, respectively.
A full recovery of vision was achieved postoperatively in 37 patients (63%), and an improvement in 16 patients (27%). The visual acuity and the visual fields were therefore improved in 90% of the patients with preoperative visual deficits. There were no instances of postoperative visual deterioration. Patients with visual symptoms understandably had larger tumors compared with patients who had no visual changes. The average vertical diameter of the suprasellar tumor extension was 18.5 mm in patients with visual symptoms and 9.5 mm in patients with no visual impairment. There was no significant correlation between the vertical dimension of the suprasellar tumor extension and the postoperative visual improvement. The same was true for the tumor shape and texture.
Five patients (4.6%) presented with oculomotor abnormalities. One patient developed sudden and severe headaches, signs of meningeal irritation, and a third nerve paralysis, and was initially diagnosed as having a ruptured posterior communicating artery aneurysm.
Completeness of Tumor Removal. A postoperative CT scan was obtained in 92 patients. Table 2 shows the timing of the postoperative CT scan in relation to surgery and postoperative radiation therapy. In 40 patients the postoperative CT scan was obtained either immediately following or within 6 weeks after surgery. There was no evidence of demonstrable residual tumor tissue in 17 patients (41%). A CT scan was also obtained during follow-up studies in 52 additional patients operated on many months or years previously. This delayed CT scan revealed no residual tumor tissue in 10 patients who did not receive radiation therapy or any other form of treatment following surgery, and in 30 other patients who were irradiated postoperatively. Ten of the patients in the latter group were scanned within 6 months of the completion of their radiation therapy. There was no appreciable difference when results ob- Results of Endocrine Studies. The majority of patients harbored prolactin-secreting tumors (38%), but nearly one-third of the patients had nonsecreting adenomas. Table 3 demonstrates the preoperative and postoperative hormonal values in our patients. Cure of endocrine symptoms was achieved in only 27% of patients with prolactin-secreting tumors and in 20% of patients with growth hormone-secreting macroadenomas.
Tumor Recurrences
Classification. There was a total of 13 recurrences (12.7%) among the 102 patients in whom a follow-up review was possible. Recurrences were classified into three categories: those with clinical symptoms, those seen on CT scanning without clinical symptoms, and those with endocrinological evidence. A patient was considered to have a clinical recurrence when either old visual symptoms returned or a new visual deficit occurred and neuroradiological studies confirmed the presence of recurrent tumor growth. Eight patients (7.8%) had clinical recurrences. Table 4 shows the incidence of clinical recurrences in relation to the follow-up period. The incidence of clinical recurrences was between 15% and 18% among patients followed from 4 to 8 years. There were no recurrences in patients followed for less than 2 and over 10 years. Only two patients (2.4%) had CT evidence of recurrence without clinical symptoms among 84 patients followed for 6 months or longer. A sustained rise of a pituitary hormone over a 12-month period was classified as recurrent endocrinopathy. Among 71 patients followed with endocrinological testing, there were three such recurrences (4.2%).
Correlation with Tumor Size and Growth. Correlation of tumor dimensions and of their growth characteristics with the rate of recurrences showed a recurrence rate of 6% to 13% when the vertical diameter of the suprasellar tumor extension was less than 2 cm and 42% when it exceeded 2 cm (Table 5 ). Hard septate tumors had a somewhat higher rate of recurrence (28 %) compared with cystic (11%) and soft tumors (6%). On the other hand, the incidence of recurrence was not appreciably different in patients with straight (13%) and asymmetric suprasellar tumor extension (9%). Similarly, the invasiveness of a pituitary adenoma did not seem to influence the recurrence rate. Invasive tumors recurred in 15% of cases and noninvasive tumors in 12% of cases.
Nine (28%) of 32 patients with pituitary macroad- enomas who did not receive postoperative radiation therapy developed a recurrence. In contrast, only four (6%) of 67 patients who were irradiated postoperatively suffered a recurrence of their tumor. A 50% incidence of recurrence was found in patients with incompletely removed tumors who did not receive postoperative radiation therapy. The recurrence rate was also higher in patients with a gross total tumor removal who did not receive postoperative radiation therapy (21%) compared to patients with incompletely removed tumors who were irradiated (10%). There were no recurrences in patients with a gross total tumor removal who received postoperative radiation therapy.
Discussion
The presence of visual symptoms in patients with large pituitary tumors will depend on the anatomy of the optic nerves and chiasm and the compression exerted by the tumor. In addition to compromising the optic system by a straight suprasellar extension, a pituitary tumor can also cause optic nerve compression by insinuating itself into the optic nerve canal in patients with intrasphenoidal tumor extension. The overall incidence of visual improvement in this series was comparable to the results previously reported in the literature for both the transcranial and transsphenoidal approaches. 2)'39 In most of our patients the postoperative visual improvement was quite rapid, with noticeable visual recovery occurring usually within 12 to 24 hours after surgery. The postoperative visual improvement did not depend on the size of the suprasellar tumor extension, the direction of its growth, the tumor consistency, or its invasiveness into the surrounding structures. When a CT scan was obtained immediately after surgery, acute postoperative changes could not always be distinguished from residual tumor mass, frequently displaced into its original location above the diaphragma sellae by the sella pack. As the sella pack fibrosed and partially resorbed within a few weeks after surgery, the arachnoid membrane and the remaining tumor tissue descended once again toward the sella floor. Consequently, it is thought that postponing the first postoperative CT scan for a few weeks after surgery provides more reliable information as to the presence and final location of a residual tumor mass. The surgeon's ability to perform a gross total tumor removal with no demonstrable evidence of a residual tumor tissue on the postoperative CT scan appears to be influenced by the diameter of the suprasellar tumor extension and the consistency of the tumor. Specifically, suprasellar tumor extension of more than 2 cm and the presence of many tough fibrous septa dividing the tumor parenchyma into compartments have made such a removal difficult or impossible.
As previously suggested in the literature, 6 this study has also shown that postoperative radiation therapy plays an important role in prevention of recurrences. Two of 67 patients who received postoperative radiation therapy developed a visual defect 11 and 18 months after the completion of radiation therapy. The delivery of radiation therapy in these two patients (5100 and 5400 fads in 25 and 30 fractionated dosages, respectively) did not differ essentially from the treatment plan in the other patients.
The salutary effect ofbromocriptine on hyperprolactinemia, galactorrhea, and infertility has been well known for almost a decade. 4'8'1~ Discontinuation of bromocriptine therapy, however, results in a recurrence of hyperprolactinemia in the majority of patients. 1,4,1~176 Evidence is also available showing that bromocriptine can inhibit pituitary tumor growth in experimental animals. 23 '27 Since 1978, a number of reports have been published describing improvement in visual fields TM and regression in the size of pituitary tumors in patients treated with bromocriptine. 1,2,7,14,19,24.25,28-30.32,36,37 In a series of 18 patients with large prolactin-secreting pituitary tumors treated with bromocriptine, 80% of whom showed a reduction in their tumor size, the tumor bulk and the visual deficit returned to the pretreatment level in six patients when bromocriptine therapy was discontinued. 3~ Consequently, Thorner 3~ emphasized that bromocriptine therapy is suppressive rather than curative. He also warned that caution should be exercised when withdrawing bromocriptine from patients who harbored large prolactin-secreting tumors. 34 Ambrosi, et al.,~ concluded that bromocriptine should not be viewed as an exclusive therapy but rather as an adjuvant therapeutic modality to be used prior to or following incomplete removal of a large prolactin-secreting pituitary tumor. Symptomatic and objective clinical improvement has been observed in acromegalic patients treated with bromocriptine. 38 Nevertheless, a return of the serum growth hormone level to normal (under 5 ng/ml) and a reduction in the size of a growth hormone-secreting adenoma are not always predictable, and occur in a relatively small number of patients.l,22,37 Bromocriptine does not influence appreciably the size of ACTH-secreting tumors.l Recently, we have used bromocriptine pre-or postoperatively in three cases of prolactin-secreting macroadenomas each. In one patient with a large and invasive tumor who was treated with bromocriptine prior to surgery, the tumor consisted mostly of fibrous septa with a sparse amount of hemorrhagic tumor parenchyma. A similar observation was made by Landolt, et al., 18 who also found fewer endocrine cures in patients with microadenomas treated preoperatively with bromocriptine. They concluded that bromocriptine may cause fibrosis of the otherwise soft tumor parenchyma, making complete extirpation of a microadenoma more difficult. 18 In another patient, we found the usually well developed pseudocapsular cleavage plane between the tumor and the normal anterior pituitary 5 less distinct, making a tumor resection along its margin more difficult. In the third patient treated with bromocriptine prior to surgery there was no evidence of a decrease in tumor size. All three patients with incompletely removed tumors who were treated with bromocriptine postoperatively showed a significant regression in the size of their residual tumor mass.
Summary
One hundred eight patients with pituitary macroadenomas who underwent a total of 117 transsphenoidal operations and five craniotomies were followed from 6 months to 14 years postoperatively. Visual improvement occurred in 90% of patients with preoperative visual impairment. Visual improvement did not appear to be influenced by the tumor size, consistency, direction of growth, or invasiveness into the surrounding structures. Gross total tumor removal as judged from the immediate postoperative CT scan was possible in 41% of patients. Gross total tumor removal was rarely possible in patients with a suprasellar tumor extension of greater than 2 cm. An endocrine cure was possible in only one-fourth of prolactin-secreting and in onefifth of growth hormone-secreting pituitary macroadenomas. Thus, the absence of residual tumor tissue on the postoperative CT scan is only significant within the limitation of the resolution capabilities of a CT scan. The incidence of recurrences for the entire series was 12.7%. The greatest number of recurrences occurred from 4 to 8 years postoperatively. Postoperative radiation therapy appears to play a greater role than the completeness of tumor removal in the prevention of recurrences. When the postoperative CT scan was negative for residual tumor tissue and radiation therapy was withheld, the incidence of recurrences was 21%. There were no recurrences, however, when a similar group of patients received postoperative radiation therapy. Bromocriptine appears to be an excellent adjuvant therapy for patients with incompletely removed tumors in whom it may significantly reduce the size of the residual tumor mass. Preoperative administration of bromocriptine can make tumor removal along its natural cleavage planes more difficult.
